Industrial Perspective on the Benefits Realized From the FDA’s Model‐Informed Drug Development Paired Meeting Pilot Program
Open Access
- 15 May 2021
- journal article
- editorial
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 110 (5) , 1172-1175
Abstract
No abstract availableKeywords
This publication has 3 references indexed in Scilit:
- The US Food and Drug Administration's Model‐Informed Drug Development Paired Meeting Pilot Program: Early Experience and ImpactClinical Pharmacology & Therapeutics, 2019
- Model‐Informed Drug Discovery and Development: Current Industry Good Practice and Regulatory Expectations and Future PerspectivesCPT: Pharmacometrics & Systems Pharmacology, 2018
- Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug DevelopmentClinical Pharmacology & Therapeutics, 2013